trial

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

NCTId NCT07227818
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 560 (estimated)
Sponsored by Neurocrine Biosciences
Primary completion 2029-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
560 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-12-16
Primary completion
2029-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
NBI-1117568

Sponsors

Neurocrine BiosciencesLead Sponsor

Investigators

1
Clinical Development LeadStudy Director

Sites

20 total
Garden Grove, United StatesLa Habra, United StatesLemon Grove, United StatesOceanside, United StatesTorrance, United StatesWest Hills, United StatesHollywood, United StatesMaitland, United StatesMiami, United StatesMiami, United StatesTampa, United StatesWest Palm Beach, United States

Linked catalysts

1
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia — primary completion2029-07

Facts & assertions

4 sourced
Enrollment
560
Phase
PHASE3
Primary Completion Date
2029-07
Status
RECRUITING
relationships
The graph out of here
drug
NBI-1117568
drug
lead_sponsor
Neurocrine Biosciences
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Clinical Development Lead
person